Chemoradiotherapy for Patients With Locally Advanced Nasopharyngeal Carcinoma Using Raltitrexed-Cisplatin

NCT ID: NCT02562599

Last Updated: 2022-02-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-08-31
• Study Completion Date: 2018-08-31

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of raltitrexed and cisplatin neoadjuvant chemotherapy followed by concurrent radiotherapy with raltitrexed and cisplatin in patients with locally advanced nasopharyngeal carcinoma.

Detailed Description

Although concurrent chemoradiation is the standard treatment modality for locally advanced nasopharyngeal carcinoma (NPC), high incidences of distant metastases and severe treatment related toxicities have become an obstacle to be overcome. A phase Ⅱ study conducted by Hui et al. showed that neoadjuvant chemotherapy followed by concurrent chemoradiotherapy was superior to the standard concomitant chemoradiation in terms of the 3-year OS without significantly exacerbating the acute toxicities.

At present, PF regimen has been considered as the most classic chemotherapy regimen of nasopharyngeal carcinoma (NPC), but its efficiency is about 40%-60% , and always with severe gastrointestinal reactions, renal toxicity and oral mucosa reaction. Therefore, it is imperative to find a more safe and effective chemotherapy regimen.

Raltitrexed is a specific thymidylate synthase inhibitor with a convenient administration schedule,acceptable and manageable toxicity, radiosensitising properties. It may offer advantages compared with standard 5-FU chemotherapy regimens used in locally advanced NPC.

Therefore, the investigators initiated this study to evaluate the efficacy and safety of raltitrexed and cisplatin neoadjuvant chemotherapy followed by concurrent radiotherapy with raltitrexed and cisplatin in patients with locally advanced NPC.

Conditions

Nasopharyngeal Carcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

drug:raltitrexed safety and efficacy

To receive the safety and efficacy of raltitrexed-cisplatin neoadjuvant chemotherapy followed by concurrent chemoradiotherapy with raltitrexed-cisplatin

Interventions:

Neochemotherapy (Induction Chemotherapy) Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles).

Concurrent Chemotherapy Drugs: raltitrexed-cisplatin (Raltitrexed, 2.5mg/m2, IV in 15 minutes, d1; Cisplatin, 25mg/m2, IV, d1-3.Cycled every 21 days for 2 cycles) .

Radiation: Intensity-modulated radiotherapy (IMRT)

Group Type: EXPERIMENTAL

raltitrexed-cisplatin

Intervention Type: DRUG

Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles

Intensity-modulated radiotherapy (IMRT)

Intervention Type: RADIATION

Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles

Interventions

raltitrexed-cisplatin

Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles

Intervention Type: DRUG

Intensity-modulated radiotherapy (IMRT)

Patients receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles

Intervention Type: RADIATION

Other Intervention Names

Tomudex

Eligibility Criteria

Inclusion Criteria

1. Patients with newly histologically confirmed nasopharyngeal carcinoma, including WHO III

2. Newly diagnosed T3-4 or any TN2-3 locally advanced nasopharyngeal carcinoma

3. At least one measurable lesion (according to the RECIST1.1)

4. female and male,18-70 years of age

5. ECOG performance status of 0-1

6. Life expectancy of more than 3 months

7. Without radiotherapy or chemotherapy

8. Adequate organ function including the following:

Platelets count >= 100 * 109/l Absolute neutrophil count (ANC) >= 2.0 * 109/l Hemoglobin >= 90 g/l Total bilirubin <= 1.5ULN AST and ALT <= 2.5ULN,if there is liver metastasis , AST and ALT <= 5ULN Serum creatine <= 1.5ULN

9. Signed and dated informed consent.

Exclusion Criteria

1. Before or at the same time any second malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix

2. Evidence of distant metastasis

3. Taboos of chemotherapy or radiotherapy(such as heart failure, angina pectoris, or cardiac arrhythmia.et al) Presence of an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia

4. Pregnant or breast-feeding females

5. Abuse of psychiatric drugs or dysphrenia

6. Prior chemotherapy with raltitrexed or cisplatin

7. Allergic to clinical drugs

8. Participation in clinical trials for other anti-tumor drugs in 4 weeks

9. Evidence of significant medical illness that in the investigator's judgment will substantially increase the risk associated with the subject's participation in and completion of the study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hubei Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

HU DESHENG

Associate dean

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Desheng Hu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Associate dean

Locations

Hubei Cancer hospital

Wuhan, Hubei, China

Countries

China

Other Identifiers

Radiotherapy center-001

Identifier Type: -

Identifier Source: org_study_id